Maven Securities LTD Acquires New Holdings in Kymera Therapeutics, Inc. $KYMR

Maven Securities LTD acquired a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) in the 4th quarter, Holdings Channel.com reports. The fund acquired 15,000 shares of the company’s stock, valued at approximately $1,167,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. US Bancorp DE grew its position in shares of Kymera Therapeutics by 9.8% in the 3rd quarter. US Bancorp DE now owns 1,865 shares of the company’s stock valued at $106,000 after purchasing an additional 166 shares during the period. Larson Financial Group LLC grew its position in shares of Kymera Therapeutics by 36.9% in the 4th quarter. Larson Financial Group LLC now owns 1,064 shares of the company’s stock valued at $83,000 after purchasing an additional 287 shares during the period. State Board of Administration of Florida Retirement System grew its position in shares of Kymera Therapeutics by 3.3% in the 4th quarter. State Board of Administration of Florida Retirement System now owns 12,655 shares of the company’s stock valued at $985,000 after purchasing an additional 410 shares during the period. Smartleaf Asset Management LLC grew its position in shares of Kymera Therapeutics by 382.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after purchasing an additional 424 shares during the period. Finally, Xponance LLC grew its position in shares of Kymera Therapeutics by 13.1% in the 4th quarter. Xponance LLC now owns 4,505 shares of the company’s stock valued at $351,000 after purchasing an additional 522 shares during the period.

Insider Activity

In other Kymera Therapeutics news, Director Bruce Booth sold 5,900 shares of the company’s stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $89.96, for a total transaction of $530,764.00. Following the completion of the transaction, the director owned 5,641 shares of the company’s stock, valued at $507,464.36. This represents a 51.12% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jeremy G. Chadwick sold 91,250 shares of the company’s stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $77.41, for a total value of $7,063,662.50. Following the transaction, the chief operating officer directly owned 61,202 shares of the company’s stock, valued at approximately $4,737,646.82. This trade represents a 59.85% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 234,357 shares of company stock worth $19,072,496. 15.98% of the stock is currently owned by insiders.

Analyst Ratings Changes

KYMR has been the subject of several research analyst reports. Royal Bank Of Canada reiterated an “outperform” rating and issued a $108.00 price objective on shares of Kymera Therapeutics in a research report on Thursday, February 26th. UBS Group boosted their price objective on Kymera Therapeutics from $90.00 to $128.00 and gave the company a “buy” rating in a research report on Tuesday, March 3rd. Loop Capital set a $97.00 price objective on Kymera Therapeutics in a research report on Monday, June 8th. BTIG Research decreased their price objective on Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $119.00 price objective on shares of Kymera Therapeutics in a research report on Thursday, April 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $117.14.

Kymera Therapeutics Price Performance

NASDAQ:KYMR opened at $86.21 on Monday. Kymera Therapeutics, Inc. has a twelve month low of $36.65 and a twelve month high of $103.00. The business has a 50 day moving average price of $82.85 and a two-hundred day moving average price of $80.32. The company has a market cap of $7.09 billion, a P/E ratio of -24.15 and a beta of 2.02.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The firm had revenue of $34.37 million during the quarter, compared to the consensus estimate of $8.27 million. During the same quarter in the prior year, the firm posted ($0.82) EPS. The business’s revenue was up 55.5% on a year-over-year basis. As a group, analysts anticipate that Kymera Therapeutics, Inc. will post -3.25 earnings per share for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.